MedTrace Logo

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

NCT04920786 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-12-09

No results posted yet for this study

Summary

This is a single dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as a disease modifying treatment for Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

TB006

TB006

OTHER

Sterile saline (Placebo)

Sterile saline

Sponsors & Collaborators

  • TrueBinding, Inc.

    lead INDUSTRY

Principal Investigators

  • George Haig, PharmD · TrueBinding, Inc.

  • David Walling, MD · Collaborative Neuroscience Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-05-03
Completion
2022-05-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920786 on ClinicalTrials.gov